Pharmacokinetic Study of NADPH Oxidase Inhibitor Ewha-18278, a Pyrazole Derivative
Open Access
- 17 September 2019
- journal article
- research article
- Published by MDPI AG in Pharmaceutics
- Vol. 11 (9) , 482
Abstract
In a previous study, the specific NOX1/2/4 inhibitor Ewha-18278 was confirmed as a possible treatment for osteoporosis both in vitro and in vivo. Here, we investigated the pharmacokinetics (PK) of the compound by intravenous (IV) and oral administrations to rats. Dimethyl sulfoxide (DMSO)-based and diazepam injection-based formulations were used to dissolve the compound. In the latter formulation applicable to humans, the changes in PK parameters were monitored at two different concentrations (1 mg/mL and 2 mg/mL). The area under the plasma concentration-time curve from zero time to infinity (AUCinf) of Ewha-18278 was highest in the DMSO-based formulation (2 mg/mL). Also, the concentration was increased 1.6-fold at the low concentration of the diazepam injection-based formulation compared to the high concentration. There was no statistical significance in the AUCinf of the compound between DMSO-based formulation (2 mg/mL) and diazepam injection-based formulation (1 mg/mL). These results suggest that Ewha-18278 can be delivered to humans by both IV and oral routes. In addition, the diazepam injection-based formulation of Ewha-18278 appears to be a suitable candidate for dosage development for future toxicity test and clinical trial.Keywords
Funding Information
- National Research Foundation of Korea (2017R1A2B4007869)
This publication has 16 references indexed in Scilit:
- Expand classical drug administration ways by emerging routes using dendrimer drug delivery systems: A concise overviewAdvanced Drug Delivery Reviews, 2013
- Effects of silymarin and formulation on the oral bioavailability of paclitaxel in ratsEuropean Journal of Pharmaceutical Sciences, 2012
- NOX enzymes in immuno-inflammatory pathologiesSeminars in Immunopathology, 2008
- Salt formation to improve drug solubilityAdvanced Drug Delivery Reviews, 2007
- The NOX Family of ROS-Generating NADPH Oxidases: Physiology and PathophysiologyPhysiological Reviews, 2007
- Free radicals and antioxidants in normal physiological functions and human diseaseThe International Journal of Biochemistry & Cell Biology, 2007
- Formulation of poorly water-soluble drugs for oral administration: Physicochemical and physiological issues and the lipid formulation classification systemEuropean Journal of Pharmaceutical Sciences, 2006
- A crucial role for reactive oxygen species in RANKL-induced osteoclast differentiationBlood, 2005
- Solubilizing Excipients in Oral and Injectable FormulationsPharmaceutical Research, 2004
- An integrated approach to the selection of optimal salt form for a new drug candidateInternational Journal of Pharmaceutics, 1994